The optimal management of aHUS: From diagnosis to treatment
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released:
EXPIRED
Valid for credit through:
EXPIRED
CME accredited by:
The Hong Kong College of Family Physicians - 1
Hong Kong College of Paediatricians - 1
The Hong Kong College of Pathologists - 1
Hong Kong College of Physicians - 0.5
Hong Kong College of Community Medicine - 0.5
Hong Kong College of Emergency Medicine - 0.5
Endorsed by:
Hong Kong Society of Nephrology
About the programme
Atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP) require different treatment approaches. Early identification and treatment of the two conditions are crucial to improve the significant mortality and morbidity associated with thrombotic microangiopathy (TMA). A systematic investigation coupling with specific treatment approaches can prevent the loss of kidney function and improve the survival of TMA patients.1
In this video, Dr. Manuel Praga Terente from the Hospital Universitario 12 de Octubre, Madrid, described the diagnostic methods to differentiate aHUS and TTP early and the appropriate treatments to be initiated once a clear clinical diagnosis is made.
References:
1. Brocklebank V et al. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2):300-317.
Professor Manuel Praga Terente
Research Institute,
Hospital 12 de Octubre,
Madrid Spain
Disclosure:
Professor Manuel Praga Terente has disclosed the following relevant financial relationships:
- Served as a consultant for Astra-Zeneca, Alexion, Retrophin, Pharmalink, Otsuka and Fresenius
- Served as an advisory board member for Abbvie, Astra-Zeneca, Alexion, Retrophin, Pharmalink and Otsuka
- Served as a speaker for Abbvie, Astra-Zeneca, Astellas, Alexion, Retrophin, Pharmalink, Otsuka and Fresenius
- Research funding sponsored by Amgen, Sandoz and Novartis
Disclaimer
This is an educational programme developed through unrestricted support from DKSH Hong Kong Limited, for the purpose of continuing medical education only. The views expressed on this portal reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.